

Alder Biopharmaceuticals Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 03-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Subsidiary Companies..... 12

Product Portfolio Summary..... 12

Product Portfolio Financials..... 17

Product Portfolio Drugs..... 17

[Return to Table of Contents](#)

Alder Biopharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Alder Biopharmaceuticals Inc
Parent Company Name	Alder Biopharmaceuticals Inc
Website	http://www.alderbio.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	6
Number of Patents as Owner	19
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Rheumatoid arthritis, Anemia, Cachexia, Fatigue, Graft versus host disease, Migraine, Pain, Psoriatic arthritis, Crohns disease, Cushings disease, Oral mucositis
Key Target-based Actions	Hepatocyte growth factor antagonist, NGF receptor antagonist, CGRP receptor antagonist, IL-6 antagonist, Proprotein convertase PC9 inhibitor, ACTH receptor antagonist, Interleukin-6 ligand inhibitor, Albumin agonist, C-reactive protein inhibitor, Albumin modulator, C-reactive protein modulator, CD126 antagonist, CGRP receptor agonist, Cytokine receptor agonist, Hepatocyte growth factor agonist, Interferon antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Jak3 tyrosine kinase inhibitor, LDL receptor agonist, MAP kinase inhibitor, NGF receptor agonist, Proprotein convertase PC9 stimulator, STAT-3 inhibitor, Syk tyrosine kinase inhibitor, TNF alpha ligand, Triosephosphate dehydrogenase modulator, p38 MAP kinase inhibitor
Key Technologies	Biological therapeutic, Parenteral formulation unspecified, Monoclonal antibody humanized, Monoclonal antibody, Intravenous formulation, Protein recombinant, Subcutaneous formulation, Infusion, Antibody fragment, Antibody

COMPANY PROFILE

SUMMARY

Alder Biopharmaceuticals Inc, founded in January 2004, is focused on the identification, development and manufacture of antibody therapeutics for cancer, inflammatory, autoimmune and cardiovascular diseases.

LICENSING AGREEMENTS

In December 2005, Alder agreed to identify and manufacture Schering-Plough's antibody therapeutics. Using its yeast production system and high throughput antibody selection technology, Alder would work on up to ten Schering-Plough antibodies. Alder would receive milestone payments, research support and royalties. In June 2009, the agreement was expanded to include candidates with potential applications to central nervous system disorders. Alder would receive an upfront payment, milestones, royalties and committed funding for Alder personnel engaged in the project.

In November 2005, Alder agreed to use its yeast production system to produce research materials for one of Seattle Genetics' preclinical therapeutic antibodies.

FINANCIAL

In January 2015, a public offering of 4 million shares of company's common stock was initiated; underwriters were to be granted a 30-day option to purchase up to 600,000 additional shares at the public offering price. Later that month, the company priced the underwritten public offering of 6 million shares at \$29.50 each and also granted the underwriters a 30-day option to purchase up to 0.9 million additional shares. At that time, the offering was expected to close on January 13, 2015. Later, in January 2015, the underwriters exercised their option to purchase an additional 0.9 million shares of common stock, and the company raised \$203.6 million through the offering of 6.9 million shares.

In December 2014, the company was added to the NASDAQ Biotechnology Index (NBI) which would become effective

[Return to Table of Contents](#)



upon market open on December 22, 2014.

In June 2014, the company was added to the Russell 3000 Index.

In May 2014, the company announced the pricing of its initial public offering of 8 million shares of its common stock at a price of \$10 per share. The shares had begun trading on the NASDAQ Global Market under the ticker symbol "ALDR". Alder had granted the underwriters a 30-day option to buy up to 1.2 million additional shares of common stock at the initial public offering price to cover over-allotments, if any. The offering was expected to close on May 13, 2014. Later that month, the offering was closed and the company raised net proceeds of \$80.1 million from the sale of an aggregate of 8,875,396 shares of its common stock, including 875,396 shares pursuant to the partial exercise of the underwriters' over-allotment option.

In April 2012, the company closed a \$38 million series D financing.

In January 2007, Alder raised \$40 million from a series C financing round.

In July 2006, Alder raised \$16 million in a series B financing round.

In August 2005, Alder raised \$11.1 million in a series A financing.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	26.89
Change (USD)	-0.63 (-2.29%)
Previous Close Price (USD)	27.52
Volume	244,990
52-Week High (USD)	32.30
52-Week Low (USD)	9.50
Date	02-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	37,923,916
Current Market Capitalization	1,078,176,932
EPS (Date Reported)	0.30271

[Return to Table of Contents](#)


STOCK PERFORMANCE



MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Latham (John A)	Individual Investor	United States	208,988	0.55	0	0	01-Apr-2015

[Return to Table of Contents](#)



	2012	2011	2014	2013	
Sales (USD M)	20.067	21.822	54.705	18.796	
Operating Income (USD M)	-17.819	-13.111	8.804	-20.761	
Net Income (USD M)	-17.806	-13.319	8.908	-20.613	

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	6.436	-6.967	-6.942
2014 Q3	38.784	28.579	28.611539
2014 Q2	4.703	-7.41	-7.401
2014 Q1	4.782	-5.398	-5.395
2013 Q4	4.824	-3.818	-3.875
2013 Q2	4.663	-5.123	-5.147
2013 Q1	4.599	-5.704	-5.682
2012 Q4	4.775	-4.104	-4.074

BALANCE SHEET

Assets (USD M)

	2011	2012	2013	2014
Cash & Short Term Investments	52.402	59.373	23.227	55.872
Inventories - Total	0	0	0	0
Current Assets - Total	56.961	62.536	25.525	60.743
Property, Plant And Equipment - Net	2.01	1.999	1.214	1.16
Other Assets - Total	0	0	0	2.456
Total Assets	59.09	64.654	26.739	64.359

Liabilities (USD M)

	2011	2012	2013	2014
Accounts Payable	2.143	1.92	2.223	1.911
Short Term Debt & Current Portion Of Long Term Debt	5.791	0	0	0
Current Liabilities - Total	27.424	22.598	23.068	5.009
Long Term Debt	0	0	0	0
Other Liabilities	0.181	0.014	0.052	0.193
Total Liabilities	97.566	76.664	58.727	5.202

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2011	2012	2013	2014	
Minority Interest	0	0	0	0	
Preferred Stock	67.638	111.374	111.374	0	
Common Stock	0	0	0	0.003	
Treasury Stock			0	0	
Total Liabilities & Shareholders' Equity	59.09	64.654	26.739	64.359	

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.59	-1.66	-1.59
31-Dec-2016	-1.62	-1.78	-1.62
31-Dec-2017	-1.92	-2.21	-1.92

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	-1.4	-62.85	1.03
31-Dec-2016	0	-0.7	-68.18	20.7
31-Dec-2017	0	-2.46	-89.82	19.03

SUBSIDIARY COMPANIES

Names
AlderBio Holdings LLC

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	2	1	3
Inflammatory disease	1	1	2
Metabolic disorder	1	1	2
Hematological disease	1	1	2
Neoplasm	0	2	2
Fatigue	1	0	1
Endocrine disease	1	0	1
Nutritional disorder	1	0	1
Musculoskeletal disease	1	0	1
Immune disorder	1	0	1
Gastrointestinal disease	1	0	1
Cardiovascular disease	0	1	1
Mouth disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Discovery	2
No Development Reported	6

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	0	0	1
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Development/Commercialization License	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neurological disease	1	4
Nutritional disorder	0	4
Fatigue	0	3
Immune disorder	0	3
Musculoskeletal disease	0	2
Inflammatory disease	0	2
Neoplasm	0	2
Hematological disease	0	1
Respiratory disease	0	1
Mouth disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	1	5
Phase 1	0	6

Phase Definitions

[Return to Table of Contents](#)



Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Endocrine disease	5	0	5
Gastrointestinal disease	8	0	8
Genitourinary disease	3	0	3
Growth disorder	1	0	1
Hematological disease	3	0	3
Degeneration	3	0	3
Immune disorder	6	0	6
Psychiatric disorder	1	0	1
Musculoskeletal disease	6	0	6
Neoplasm	10	0	10
Ocular disease	2	0	2
Metabolic disorder	4	0	4
Neurological disease	6	0	6
Nutritional disorder	6	0	6
Respiratory disease	3	0	3
Infectious disease	4	0	4
Injury	2	0	2
Inflammatory disease	7	0	7
Fatigue	4	0	4
Temperature disorder	2	0	2

[Return to Table of Contents](#)




Dermatological disease	1	0	1
------------------------	---	---	---

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2019



[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

clazakizumab

Drug Name	clazakizumab
Key Synonyms	clazakizumab
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	Bristol-Myers Squibb Co
Highest Status	Phase 2 Clinical
Active Indications	Anemia, Oral mucositis, Graft versus host disease, Cachexia, Fatigue, Crohns disease, Psoriatic arthritis, Rheumatoid arthritis
Target-based Actions	IL-6 antagonist
Other Actions	Anti-inflammatory
Technologies	Monoclonal antibody humanized, Subcutaneous formulation, Intravenous formulation, Infusion, Biological therapeutic, Protein recombinant
Last Change Date	15-Dec-2014

ALD-403

Drug Name	ALD-403
Key Synonyms	
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Migraine
Target-based Actions	CGRP receptor antagonist
Other Actions	
Technologies	Monoclonal antibody humanized, Subcutaneous formulation, Intravenous formulation, Infusion, Biological therapeutic, Protein recombinant
Last Change Date	10-Mar-2015

[Return to Table of Contents](#)



ALD-906

Drug Name	ALD-906
Key Synonyms	
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Pain
Target-based Actions	NGF receptor antagonist
Other Actions	Analgesic
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	22-Nov-2012

ALD-1613

Drug Name	ALD-1613
Key Synonyms	
Originator Company	Alder Biopharmaceuticals Inc
Active Companies	Alder Biopharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cushings disease
Target-based Actions	ACTH receptor antagonist
Other Actions	
Technologies	Monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified
Last Change Date	28-Jan-2015

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)